Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

13.73
-0.1600-1.15%
Pre-market: 13.920.1900+1.38%04:39 EDT
Volume:2.99M
Turnover:41.89M
Market Cap:1.64B
PE:-13.20
High:14.42
Open:14.25
Low:13.70
Close:13.89
Loading ...

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
26 Feb

Arcutis Biotherapeutics announces publication of data from INTEGUMENT-PED trial

TIPRANKS
·
24 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
21 Feb

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

Zacks
·
17 Feb

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
17 Feb

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
14 Feb

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Zacks
·
13 Feb

Arcutis Biotherapeutics rumor highlighted in Betaville alert

TIPRANKS
·
13 Feb

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Zacks
·
11 Feb

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Blockhead
·
06 Feb

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Feb

Recent 4.4% pullback isn't enough to hurt long-term Arcutis Biotherapeutics (NASDAQ:ARQT) shareholders, they're still up 118% over 1 year

Simply Wall St.
·
01 Feb

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Zacks
·
28 Jan

Arcutis Biotherapeutics Receives Buy Rating Amid Strong Prescription Growth in Zoryve Franchise

TIPRANKS
·
27 Jan

Strong Prescription Growth for Arcutis Biotherapeutics’ Zoryve Franchise Supports Buy Rating

TIPRANKS
·
20 Jan

Arcutis Biotherapeutics price target raised to $20 from $18 at Needham

TIPRANKS
·
13 Jan

Arcutis Shares Climb on Strong Product Revenue Estimates

Dow Jones
·
13 Jan

Arcutis Biotherapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

Arcutis Biotherapeutics’ Robust Revenue Growth and Strategic Financial Positioning Underpin Buy Rating

TIPRANKS
·
13 Jan

Arcutis Biotherapeutics: Strong Sales and Strategic Growth Drive Buy Rating

TIPRANKS
·
13 Jan